New research reveals that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt traditional lifestyle plans.
Research printed in a leading health publication points out that while overweight people can lose a large proportion of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Individuals using these medications need to be aware of the risk of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment mass in about a year and a half.
Weighing Approaches
The study, which reviewed dozens of trials involving over 9,000 of patients, compared the results of these new drugs with older methods.
Researchers emphasize that individuals who shed pounds through dieting typically see a less rapid weight regain—around 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Doctors propose the way of the injections is key to understanding the amplified regain.
These medications mimic a natural hormone called GLP-1, which controls hunger.
"Long-term administration of the hormone concentrations far above than normal could lead to the system to produce less of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
Health authorities advise the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals contend that, given the likelihood of weight regain, the therapy might need to be ongoing.
This view is supported by drug manufacturers, who note that the findings "emphasize the long-term character of obesity," comparing it to managing diseases like hypertension.
User Accounts
Users who have stopped the jabs explain a intense return of hunger.
"I experienced a switch that goes on and you become starving," recalled an individual.
This challenge is compounded if users have not developed sustainable lifestyle or habit changes during therapy.
Significant Interest
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among women than men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers stress that while the jabs are effective agents for shedding pounds, they are not a permanent cure and maintained weight loss hinges on ongoing behavioural support.
